Header Logo

Connection

HASHEM EL-SERAG to Risk Assessment

Back to Details
This is a "connection" page, showing publications HASHEM EL-SERAG has written about Risk Assessment.
HASHEM EL-SERAG
Connection Strength
2.710
Risk Assessment
  1. PNPLA3, Obesity, and Heavy Alcohol Use in Cirrhosis Patients May Exert a Synergistic Increase Hepatocellular Carcinoma Risk. Clin Gastroenterol Hepatol. 2024 Sep; 22(9):1858-1866.e4.
    View in: PubMed
    Score: 0.116
  2. An Electronic Health Record Model for Predicting Risk of Hepatic Fibrosis in Primary Care Patients. Dig Dis Sci. 2024 Jul; 69(7):2430-2436.
    View in: PubMed
    Score: 0.115
  3. Risk Stratification Model for Hepatocellular Cancer in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2023 12; 21(13):3296-3304.e3.
    View in: PubMed
    Score: 0.108
  4. Risk stratification for hepatocellular cancer among patients with cirrhosis using a hepatic fat polygenic risk score. PLoS One. 2023; 18(2):e0282309.
    View in: PubMed
    Score: 0.106
  5. Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States. J Hepatol. 2022 02; 76(2):294-301.
    View in: PubMed
    Score: 0.096
  6. Model for end-stage liver disease-sodium underestimates 90-day mortality risk in patients with acute-on-chronic liver failure. J Hepatol. 2020 12; 73(6):1425-1433.
    View in: PubMed
    Score: 0.088
  7. Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents. Hepatology. 2020 01; 71(1):44-55.
    View in: PubMed
    Score: 0.083
  8. Temporal trend and risk determinants of hepatocellular carcinoma in chronic hepatitis B patients on entecavir or tenofovir. J Viral Hepat. 2018 05; 25(5):543-551.
    View in: PubMed
    Score: 0.076
  9. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B. J Hepatol. 2018 08; 69(2):278-285.
    View in: PubMed
    Score: 0.075
  10. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology. 2017 10; 153(4):996-1005.e1.
    View in: PubMed
    Score: 0.072
  11. The Annual Risk of Esophageal Adenocarcinoma Does Not Decrease Over Time in Patients With Barrett's Esophagus. Am J Gastroenterol. 2017 Jul; 112(7):1049-1055.
    View in: PubMed
    Score: 0.070
  12. ?Ongoing alcohol consumptions counteracts the benefits of sustained virological response in patients with well compensated hepatitis C cirrhosis: an observational study. Ann Hepatol. 2017 Jan-Feb 2017; 16(1):16-20.
    View in: PubMed
    Score: 0.069
  13. Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology. 2016 07; 64(1):130-7.
    View in: PubMed
    Score: 0.066
  14. The Updated Model: An Adjusted Serum Alpha-Fetoprotein-Based Algorithm for Hepatocellular Carcinoma Detection With Hepatitis C Virus-Related Cirrhosis. Gastroenterology. 2015 Dec; 149(7):1986-7.
    View in: PubMed
    Score: 0.064
  15. Statin use reduces risk of esophageal adenocarcinoma in US veterans with Barrett's esophagus: a nested case-control study. Gastroenterology. 2015 Nov; 149(6):1392-8.
    View in: PubMed
    Score: 0.063
  16. Coffee and Caffeine Are Associated With Decreased Risk of Advanced Hepatic Fibrosis Among Patients With Hepatitis C. Clin Gastroenterol Hepatol. 2015 Aug; 13(8):1521-31.e3.
    View in: PubMed
    Score: 0.061
  17. Risk of upper gastrointestinal cancers in patients with gastroesophageal reflux disease after a negative screening endoscopy. Clin Gastroenterol Hepatol. 2015 Feb; 13(2):280-6.
    View in: PubMed
    Score: 0.058
  18. Nonsteroidal anti-inflammatory drugs and the risk of Barrett's esophagus. Clin Gastroenterol Hepatol. 2014 Nov; 12(11):1832-9.e6.
    View in: PubMed
    Score: 0.058
  19. A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis. Gastroenterology. 2014 May; 146(5):1249-55.e1.
    View in: PubMed
    Score: 0.057
  20. A multibiomarker risk score helps predict risk for Barrett's esophagus. Clin Gastroenterol Hepatol. 2014 Aug; 12(8):1267-71.
    View in: PubMed
    Score: 0.056
  21. Barrett's esophagus suspected at endoscopy but no specialized intestinal metaplasia on biopsy, what's next? Am J Gastroenterol. 2014 Feb; 109(2):178-82.
    View in: PubMed
    Score: 0.056
  22. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis. Gut. 2014 Aug; 63(8):1229-37.
    View in: PubMed
    Score: 0.056
  23. Circulating inflammatory cytokines and adipokines are associated with increased risk of Barrett's esophagus: a case-control study. Clin Gastroenterol Hepatol. 2014 Feb; 12(2):229-238.e3.
    View in: PubMed
    Score: 0.055
  24. Statins for chemoprevention of hepatocellular carcinoma: assessing the evidence. Expert Rev Gastroenterol Hepatol. 2013 Aug; 7(6):493-5.
    View in: PubMed
    Score: 0.055
  25. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012 Dec; 10(12):1342-1359.e2.
    View in: PubMed
    Score: 0.052
  26. Finasteride and methadone use and risk of advanced hepatitis C related liver disease. Dig Dis Sci. 2012 Nov; 57(11):3004-10.
    View in: PubMed
    Score: 0.051
  27. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012 May; 142(6):1264-1273.e1.
    View in: PubMed
    Score: 0.050
  28. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Am J Gastroenterol. 2011 Apr; 106(4):563-73.
    View in: PubMed
    Score: 0.047
  29. Surveillance in Barrett's esophagus: lessons from behavioral economics. Gastroenterology. 2009 Sep; 137(3):763-5.
    View in: PubMed
    Score: 0.041
  30. Statins and the risk of colorectal carcinoma: a nested case-control study in veterans with diabetes. Am J Gastroenterol. 2009 May; 104(5):1241-8.
    View in: PubMed
    Score: 0.041
  31. Genetic association studies: from "searching under the lamppost" to "fishing in the pond". Gastroenterology. 2008 Mar; 134(3):662-4.
    View in: PubMed
    Score: 0.038
  32. Adapting the Rx-Risk-V for mortality prediction in outpatient populations. Med Care. 2006 Aug; 44(8):793-7.
    View in: PubMed
    Score: 0.034
  33. Obesity and disease of the esophagus and colon. Gastroenterol Clin North Am. 2005 Mar; 34(1):63-82.
    View in: PubMed
    Score: 0.031
  34. Survival in hepatitis C and HIV co-infection: a cohort study of hospitalized veterans. Clin Gastroenterol Hepatol. 2005 Feb; 3(2):175-83.
    View in: PubMed
    Score: 0.030
  35. The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. Am J Gastroenterol. 2005 Jan; 100(1):56-63.
    View in: PubMed
    Score: 0.030
  36. Phase 3 Validation of PAaM for Hepatocellular Carcinoma Risk Stratification in Cirrhosis. Gastroenterology. 2025 Mar; 168(3):556-567.e7.
    View in: PubMed
    Score: 0.030
  37. Psychosocial factors are the most common contraindications for antiviral therapy at initial evaluation in veterans with chronic hepatitis C. J Clin Gastroenterol. 2004 Jul; 38(6):530-4.
    View in: PubMed
    Score: 0.029
  38. Childhood GERD is a risk factor for GERD in adolescents and young adults. Am J Gastroenterol. 2004 May; 99(5):806-12.
    View in: PubMed
    Score: 0.029
  39. Is the length of newly diagnosed Barrett's esophagus decreasing? The experience of a VA Health Care System. Clin Gastroenterol Hepatol. 2004 Apr; 2(4):296-300.
    View in: PubMed
    Score: 0.029
  40. The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias? Am J Gastroenterol. 2003 Nov; 98(11):2535-42.
    View in: PubMed
    Score: 0.028
  41. Prevention of complicated ulcer disease among chronic users of nonsteroidal anti-inflammatory drugs: the use of a nomogram in cost-effectiveness analysis. Arch Intern Med. 2002 Oct 14; 162(18):2105-10.
    View in: PubMed
    Score: 0.026
  42. Diabetes increases the risk of acute hepatic failure. Gastroenterology. 2002 Jun; 122(7):1822-8.
    View in: PubMed
    Score: 0.025
  43. Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2021 11; 161(5):1657-1669.
    View in: PubMed
    Score: 0.024
  44. Preparing for the NASH Epidemic: A Call to Action. Gastroenterology. 2021 09; 161(3):1030-1042.e8.
    View in: PubMed
    Score: 0.024
  45. A Conceptual Model for Implementation and Evaluation of Interventions Across the Hepatocellular Carcinoma Care Continuum. Clin Gastroenterol Hepatol. 2022 05; 20(5):1174-1176.
    View in: PubMed
    Score: 0.024
  46. A Novel Biomarker Panel for the Early Detection and Risk Assessment of Hepatocellular Carcinoma in Patients with Cirrhosis. Cancer Prev Res (Phila). 2021 06; 14(6):667-674.
    View in: PubMed
    Score: 0.023
  47. Dietary Factors and Gastric Intestinal Metaplasia Risk Among US Veterans. Dig Dis Sci. 2021 05; 66(5):1600-1610.
    View in: PubMed
    Score: 0.022
  48. Use of Acid-Suppressant Medications After Diagnosis Increases Mortality in a Subset of Gastrointestinal Cancer Patients. Dig Dis Sci. 2020 09; 65(9):2691-2699.
    View in: PubMed
    Score: 0.021
  49. Risk Trajectories for Readmission and Death After Cirrhosis-Related Hospitalization. Dig Dis Sci. 2019 06; 64(6):1470-1477.
    View in: PubMed
    Score: 0.020
  50. Role of Age and Race in the Risk of Hepatocellular Carcinoma in Veterans With Hepatitis B Virus Infection. Clin Gastroenterol Hepatol. 2018 02; 16(2):252-259.
    View in: PubMed
    Score: 0.018
  51. Obesity and Risk of Nonalcoholic Fatty Liver Disease: A Comparison of Bioelectrical Impedance Analysis and Conventionally-Derived Anthropometric Measures. Clin Gastroenterol Hepatol. 2017 12; 15(12):1965-1967.
    View in: PubMed
    Score: 0.018
  52. Risk and Predictors of Variceal Bleeding in Cirrhosis Patients Receiving Primary Prophylaxis With Non-Selective Beta-Blockers. Am J Gastroenterol. 2016 12; 111(12):1778-1787.
    View in: PubMed
    Score: 0.017
  53. Inverse Association Between Gluteofemoral Obesity and Risk of?Barrett's Esophagus in a Pooled Analysis. Clin Gastroenterol Hepatol. 2016 10; 14(10):1412-1419.e3.
    View in: PubMed
    Score: 0.017
  54. Coffee or Tea, Hot or Cold, Are Not Associated With Risk of Barrett's Esophagus. Clin Gastroenterol Hepatol. 2016 May; 14(5):769-72.
    View in: PubMed
    Score: 0.016
  55. Fat mass by bioelectrical impedance analysis is not associated with increased risk of Barrett esophagus. J Clin Gastroenterol. 2014 Mar; 48(3):218-23.
    View in: PubMed
    Score: 0.014
  56. Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013 Nov; 11(11):1399-1412.e7.
    View in: PubMed
    Score: 0.014
  57. The risk of hepatocellular carcinoma in patients with previous malignancy. Cancer Invest. 2008 Jun; 26(5):511-5.
    View in: PubMed
    Score: 0.010
  58. Screening for hepatocellular carcinoma among veterans with hepatitis C on disease stage, treatment received, and survival. Clin Gastroenterol Hepatol. 2007 Apr; 5(4):508-12.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.